Systemic Juvenile Idiopathic Arthritis Market

Market Overview:

The 7 major systemic juvenile idiopathic arthritis markets reached a value of US$ 900 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,250 Million by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.

The systemic juvenile idiopathic arthritis market has been comprehensively analyzed in IMARC's new report titled "Systemic Juvenile Idiopathic Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Systemic juvenile idiopathic arthritis refers to a rare, chronic, autoimmune disease that affects children. This condition causes inflammation in one or more joints as well as other organs in the body, such as the liver, spleen, lymph nodes, and heart. The severity of the illness can vary widely among individuals, with some experiencing only mild symptoms while others have severe signs and complications, like disability and eye problems. The most common indications of the ailment include persistent joint pain, stiffness, and swelling. In some cases, patients suffering from this illness may experience high fever, a rash on the trunk, swollen lymph nodes, enlarged liver and spleen, inflammation of the heart's muscular tissue, etc. The diagnosis of systemic juvenile idiopathic arthritis is made by a review of detailed clinical features, medical history, and laboratory studies. A healthcare provider may perform an echocardiogram, along with a chest X-ray and CT scan, which help to rule out other possible causes. Additionally, a skin biopsy is recommended for better evaluation of the rash.

The increasing cases of immune-mediated disorders, in which the body's innate defense system mistakenly attacks and damages healthy tissues, are primarily driving the systemic juvenile idiopathic arthritis market. Besides this, the widespread adoption of non-steroidal anti-inflammatory drugs, such as naproxen, ibuprofen, diclofenac, etc., for relieving symptoms like swelling and improving survival rates in patients is also augmenting the market growth. Furthermore, the escalating utilization of physiotherapy interventions to restore flexibility as well as build strength and endurance in stiff joints is acting as another significant growth-inducing factor. Additionally, multiple key players are making extensive investments in R&D activities to launch novel assistive devices that can improve function and reduce unnecessary stresses on inflamed joints. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of biologic medications, including anakinra and canakinumab, since they target specific inflammatory molecules to minimize indications and significantly enhance the quality of life in patients, is expected to drive the systemic juvenile idiopathic arthritis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the systemic juvenile idiopathic arthritis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for systemic juvenile idiopathic arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the systemic juvenile idiopathic arthritis market in any manner.

Recent Developments:

• In April 2024, Biogen Inc. stated that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had issued a favorable opinion for TOFIDENCE (tocilizumab), a biosimilar monoclonal antibody based on ROACTEMRA. TOFIDENCE's intravenous formulation has been recommended for approval to treat systemic juvenile idiopathic arthritis.
• In January 2024, Celltrion USA submitted a Biologics License Application to the U.S. FDA for CT-P47, a biosimilar candidate to the reference medication ACTEMRA (tocilizumab). ACTEMRA is approved for a variety of conditions, including juvenile idiopathic polyarthritis, moderate to severe rheumatoid arthritis in adults, and systemic juvenile idiopathic arthritis.

Key Highlights:

• Systemic juvenile idiopathic arthritis accounts for around 10-20% of all juvenile idiopathic arthritis cases, with an incidence of 1/166,000 and a prevalence of 1/32,000 in the pediatric population.
• Although roughly 10% of systemic juvenile idiopathic arthritis patients develop overt macrophage activation syndrome, up to 30% of children show indications of subclinical macrophage activation syndrome.
• Systemic juvenile idiopathic arthritis affects both boys and girls and can appear in youngsters as early as one year old.
• In Asia, systemic juvenile idiopathic arthritis may account for the majority of all children’s arthritis.
• Systemic juvenile idiopathic arthritis appears to account for 25% of cases in India and 50% in Japan.

Drugs:

Actemra is the first therapeutic antibody created in Japan by Chugai. It is intended to inhibit the activity of IL-6, an inflammatory cytokine. It is administered intravenously and is approved for systemic juvenile idiopathic arthritis.

KINERET is the only FDA-approved interleukin-1 receptor antagonist (IL-1Ra) for the reduction of inflammation, joint swelling, and joint pain caused by moderate to severe active rheumatoid arthritis in individuals who have failed one or more disease-modifying antirheumatic drugs. KINERET is being developed to treat systemic juvenile idiopathic arthritis by inhibiting the protein interleukin-1 (IL-1).

Baricitinib refers to an orally administered, small-molecule, Janus kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of systemic juvenile idiopathic arthritis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the systemic juvenile idiopathic arthritis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the systemic juvenile idiopathic arthritis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current systemic juvenile idiopathic arthritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the systemic juvenile idiopathic arthritis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the systemic juvenile idiopathic arthritis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the systemic juvenile idiopathic arthritis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of systemic juvenile idiopathic arthritis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with systemic juvenile idiopathic arthritis across the seven major markets?
• What is the size of the systemic juvenile idiopathic arthritis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of systemic juvenile idiopathic arthritis?
• What will be the growth rate of patients across the seven major markets?
   

Systemic Juvenile Idiopathic Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for systemic juvenile idiopathic arthritis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the systemic juvenile idiopathic arthritis market?
• What are the key regulatory events related to the systemic juvenile idiopathic arthritis market?
• What is the structure of clinical trial landscape by status related to the systemic juvenile idiopathic arthritis market?
• What is the structure of clinical trial landscape by phase related to the systemic juvenile idiopathic arthritis market?
• What is the structure of clinical trial landscape by route of administration related to the systemic juvenile idiopathic arthritis market?